Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

MariMed

OTCPK:MRMD
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MRMD
OTCPK
$39M
Market Cap
  1. Home
  2. US
  3. Commercial Services
Company description

MariMed Inc. provides consulting services for the design, development, operation, management, and optimization of medical cannabis cultivation, production, and dispensary facilities. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • MariMed has significant price volatility in the past 3 months.
MRMD Share Price and Events
7 Day Returns
3.7%
OTCPK:MRMD
-1%
US Professional Services
-2.6%
US Market
1 Year Returns
-94.5%
OTCPK:MRMD
-9.1%
US Professional Services
-13.3%
US Market
MRMD Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MariMed (MRMD) 3.7% -4.3% -75% -94.5% - -
US Professional Services -1% -18% -20.3% -9.1% 15.3% 28.5%
US Market -2.6% -15.2% -22.2% -13.3% 5.7% 17.2%
1 Year Return vs Industry and Market
  • MRMD underperformed the Professional Services industry which returned -9.1% over the past year.
  • MRMD underperformed the Market in United States of America which returned -13.3% over the past year.
Price Volatility
MRMD
Industry
5yr Volatility vs Market
Related Companies

MRMD Value

 Is MariMed undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MariMed. This is due to cash flow or dividend data being unavailable. The share price is $0.1799.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MariMed's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MariMed's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
OTCPK:MRMD PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.39
OTCPK:MRMD Share Price ** OTCPK (2020-04-06) in USD $0.18
United States of America Professional Services Industry PE Ratio Median Figure of 37 Publicly-Listed Professional Services Companies 12.43x
United States of America Market PE Ratio Median Figure of 2,946 Publicly-Listed Companies 12.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MariMed.

OTCPK:MRMD PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= OTCPK:MRMD Share Price ÷ EPS (both in USD)

= 0.18 ÷ -0.39

-0.46x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MariMed is loss making, we can't compare its value to the US Professional Services industry average.
  • MariMed is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does MariMed's expected growth come at a high price?
Raw Data
OTCPK:MRMD PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.46x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
United States of America Professional Services Industry PEG Ratio Median Figure of 30 Publicly-Listed Professional Services Companies 1.1x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MariMed, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MariMed's assets?
Raw Data
OTCPK:MRMD PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.03
OTCPK:MRMD Share Price * OTCPK (2020-04-06) in USD $0.18
United States of America Professional Services Industry PB Ratio Median Figure of 58 Publicly-Listed Professional Services Companies 1.84x
United States of America Market PB Ratio Median Figure of 5,158 Publicly-Listed Companies 1.22x
OTCPK:MRMD PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= OTCPK:MRMD Share Price ÷ Book Value per Share (both in USD)

= 0.18 ÷ 0.03

5.97x

* Primary Listing of MariMed.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MariMed is overvalued based on assets compared to the US Professional Services industry average.
X
Value checks
We assess MariMed's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Professional Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Professional Services industry average (and greater than 0)? (1 check)
  5. MariMed has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

MRMD Future Performance

 How is MariMed expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MariMed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.3%
Expected Professional Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MariMed expected to grow at an attractive rate?
  • Unable to compare MariMed's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MariMed's earnings growth to the United States of America market average as no estimate data is available.
  • Unable to compare MariMed's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
OTCPK:MRMD Future Growth Rates Data Sources
Data Point Source Value (per year)
United States of America Professional Services Industry Earnings Growth Rate Market Cap Weighted Average 22.3%
United States of America Professional Services Industry Revenue Growth Rate Market Cap Weighted Average 5.4%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
OTCPK:MRMD Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
OTCPK:MRMD Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 46 -24 -81
2019-09-30 44 -26 -10
2019-06-30 36 -25 -7
2019-03-31 13 -8 -12
2018-12-31 12 -3 -14
2018-09-30 10 -2 -7
2018-06-30 8 2 -4
2018-03-31 7 1 -3
2017-12-31 6 2 -1
2017-09-30 6 3 0
2017-06-30 5 0 0
2017-03-31 4 0 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MariMed is high growth as no earnings estimate data is available.
  • Unable to determine if MariMed is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
OTCPK:MRMD Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from MariMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MRMD Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.39
2019-09-30 -0.05
2019-06-30 -0.03
2019-03-31 -0.06
2018-12-31 -0.07
2018-09-30 -0.04
2018-06-30 -0.02
2018-03-31 -0.02
2017-12-31 -0.01
2017-09-30 0.00
2017-06-30 0.01
2017-03-31 0.00

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MariMed will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of MRMD’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. MariMed's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Commercial Services companies here
  3. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access MariMed's filings and announcements here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MariMed's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MariMed has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

MRMD Past Performance

  How has MariMed performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MariMed's growth in the last year to its industry (Professional Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MariMed does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare MariMed's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MariMed's 1-year growth to the US Professional Services industry average as it is not currently profitable.
Earnings and Revenue History
MariMed's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MariMed Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

OTCPK:MRMD Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 45.60 -81.18 57.64
2019-09-30 43.85 -10.49 16.11
2019-06-30 36.02 -6.59 14.80
2019-03-31 13.28 -11.73 12.70
2018-12-31 11.85 -13.60 11.84
2018-09-30 9.99 -7.18 7.08
2018-06-30 8.32 -4.07 5.81
2018-03-31 7.00 -3.06 4.79
2017-12-31 6.07 -1.19 3.75
2017-09-30 5.92 0.13 2.65
2017-06-30 5.07 0.46 1.84
2017-03-31 4.08 -0.16 1.55
2016-12-31 3.56 -0.20 1.33

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MariMed has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MariMed has efficiently used its assets last year compared to the US Professional Services industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MariMed improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MariMed's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Professional Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MariMed has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

MRMD Health

 How is MariMed's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MariMed's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MariMed's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • MariMed's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MariMed's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MariMed Company Filings, last reported 3 months ago.

OTCPK:MRMD Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 6.33 37.74 2.19
2019-09-30 82.79 34.76 0.14
2019-06-30 82.83 35.12 3.53
2019-03-31 65.52 21.90 4.22
2018-12-31 61.76 15.25 4.10
2018-09-30 36.50 12.18 6.03
2018-06-30 21.64 16.33 5.08
2018-03-31 10.73 15.36 0.41
2017-12-31 11.01 16.32 1.29
2017-09-30 8.09 7.86 0.65
2017-06-30 5.27 6.68 2.82
2017-03-31 -0.55 6.34 0.57
2016-12-31 -0.55 6.34 0.57
  • MariMed's level of debt (596.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if MariMed's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MariMed has less than a year of cash runway based on current free cash flow.
  • MariMed has less than a year of cash runway if free cash flow continues to grow at historical rates of 55.1% each year.
X
Financial health checks
We assess MariMed's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MariMed has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

MRMD Dividends

 What is MariMed's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MariMed dividends.
If you bought $2,000 of MariMed shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MariMed's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MariMed's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
OTCPK:MRMD Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
United States of America Professional Services Industry Average Dividend Yield Market Cap Weighted Average of 21 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MariMed has not reported any payouts.
  • Unable to verify if MariMed's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MariMed's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MariMed has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MariMed's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MariMed afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MariMed has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

MRMD Management

 What is the CEO of MariMed's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Bob Fireman
COMPENSATION $96,355
AGE 70
TENURE AS CEO 2.8 years
CEO Bio

Mr. Robert N. Fireman, also known as Bob, has been Chief Executive Officer and President of MariMed Inc. since July 2017. Mr. Fireman is a Co-Founder of Me4Sure Inc and serves as its Chief Executive Officer. Mr. Fireman served as Chief Executive Officer at MariMed Advisors, Inc. His experience includes direct marketing and loyalty programs, identity security, hydroponic farming, medical billing and many other consumer facing applications. Mr. Fireman founded SmartSource Direct Inc., a subsidiary of News America Marketing (News Corp) and served as its General Manager. As an entrepreneur, he was the Founder of Consumer Card Marketing (CCMI)and serves as its Chief Executive Officer. Mr. Fireman was responsible for the development, marketing and distribution of card-based loyalty, financial and database products & services in retail, grocery and drug store chains encompassing over 50,000 stores throughout the U.S. He has been a practicing attorney for over 25 years and is the managing attorney of Fireman & Associates LLP. He has been active in the development, funding and operations of Medical Marijuana facilities over the last several years. His legal acumen, entrepreneurial experience and understanding of commercial agriculture are a tremendous asset to Fireman & Associates. Mr. Fireman joined the Worlds team as a seasoned executive in the building of technology and consumer driven companies. He has been a Director of Worlds Inc, since September 11, 2007 and Worlds Online Inc. since January 25, 2011. He serves as a Director of MariMed Inc. He serves as a Director of Me4Sure Inc. Mr. Fireman holds a BA degree from the University of Wisconsin and a JD from Suffolk University Law School.

CEO Compensation
  • Insufficient data for Bob to compare compensation growth.
  • Bob's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the MariMed management team in years:

2.1
Average Tenure
54
Average Age
  • The tenure for the MariMed management team is about average.
Management Team

Bob Fireman

TITLE
Chairman
COMPENSATION
$96K
AGE
70
TENURE
2.8 yrs

Jon Levine

TITLE
CFO, Treasurer
COMPENSATION
$80K
AGE
54
TENURE
2.8 yrs

Tim Shaw

TITLE
Chief Operating Officer

Jon Rider

TITLE
Chief Information Officer
AGE
54
TENURE
0.8 yrs

Sara Gullickson

TITLE
Vice President of Marketing
AGE
35

Ryan Crandall

TITLE
Vice President of Product & Sales
TENURE
2.1 yrs

Charlie Finnie

TITLE
Chief Strategy Officer
TENURE
1.4 yrs

Jokubas Ziburkus

TITLE
Chief Innovation Officer

James Griffin

TITLE
Board of Directors Tenure

Average tenure and age of the MariMed board of directors in years:

0.8
Average Tenure
64
Average Age
  • The average tenure for the MariMed board of directors is less than 3 years, this suggests a new board.
Board of Directors

Bob Fireman

TITLE
Chairman
COMPENSATION
$96K
AGE
70

Jon Levine

TITLE
CFO, Treasurer
COMPENSATION
$80K
AGE
54
TENURE
4.3 yrs

Dave Allen

TITLE
Independent Director
AGE
64
TENURE
0.8 yrs

Ed Gildea

TITLE
Independent Director
COMPENSATION
$120K
AGE
67

Eva Selhub

TITLE
Independent Director
AGE
51
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
03. May 19 Sell Thomas Kidrin Individual 01. May 19 01. May 19 -40,000 $3.03 $-121,200
03. May 19 Sell Thomas Kidrin Individual 01. May 19 02. May 19 -60,000 $3.20 $-186,300
X
Management checks
We assess MariMed's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MariMed has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

MRMD News

Simply Wall St News

MRMD Company Info

Description

MariMed Inc. provides consulting services for the design, development, operation, management, and optimization of medical cannabis cultivation, production, and dispensary facilities. It also develops and manages facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis, and cannabis-infused products under the Kalm Fusion, Betty’s Eddies, and Nature’s Heritage brand name. In addition, the company offers regulatory, accounting, human resources, and administrative services. It had secured 13 cannabis licenses for clients in Delaware, Illinois, Nevada, Rhode Island, Massachusetts, and Maryland. MariMed Inc. was incorporated in 2011 and is based in Norwood, Massachusetts.

Details
Name: MariMed Inc.
MRMD
Exchange: OTCPK
Founded: 2011
$39,172,738
230,292,407
Website: http://www.marimedinc.com
Address: MariMed Inc.
10 Oceana Way,
Floor 2,
Norwood,
Massachusetts, 02062,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
OTCPK MRMD Common Stock Pink Sheets LLC US USD 12. May 2017
Number of employees
Current staff
Staff numbers
89
MariMed employees.
Industry
Research and Consulting Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 05:57
End of day share price update: 2020/04/06 00:00
Last earnings filing: 2020/04/01
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.